Founded in 1993 through brothers Tom and David Gardner, The Motley Fool is helping millions of people gain monetary freedom through our website, podcasts, books, newspaper columns, radio screens and high-level investment services.
Not surprisingly, many of the world’s largest drug brands have career leaders in expanding a coronavirus vaccine; After all, they have vast resources. Some developed their own COVID-19 vaccine candidates, while others used their cash to partner with other organizations that had promising programs.
Novavax (NASDAQ: NVAX) is obviously an outlier. At the beginning of 2020, the market capitalization of biotechnology was less than $130 million. Even after a noticeable increase in percentage costs so far this year, Novavax remains only a fraction of the length of other drug brands with leading applicants for coronavirus vaccines.
But can little Novavax beat his much larger rivals in the race for the coronavirus vaccine?
There is no doubt that Novavax deserves to be identified as one of the leaders in the progression of coronavirus vaccines. On September 8, nine biopharmaceutical CEOs jointly issued a press release on their commitment to “support science” to ensure the protection of their Novavax CEO Stanley Erck is one of them, and their company is the smallest in the group.
Only 10 applicants for the coronavirus vaccine have tests at a complex level, and Novavax NVX-CoV2373 is one of them. Only part of these vaccines are likely to succeed in the U. S. market. While Novavax is achieving its complex-level analysis of NVX-CoV2373 in the UK at only this level, it plans to begin a Phase 3 exam in the United States soon.
Novavax is well above its weight elegance when it comes to entering into agreements of origin for its coronavirus vaccine program. More importantly, biotechnology has signed a $1. 6 billion agreement with Operation Warp Speed to fund the complex progression of NVX-CoV2373 and obtain a hundred million doses of the vaccine to the United States if it obtains regulatory approval. Novavax has also signed an agreement with the UK to obtain 60 million doses and has reached a previous agreement with Canada to obtain up to 76 million doses.
It is certainly difficult to compare vaccine applicants only on the basis of initial clinical outcomes in the early stages; However, there is an explanation as to why Novavax NVX-CoV2373 compares quite well with other leaders in the race for the coronavirus vaccine.
Probably the biggest fear of any experimental vaccine is its safety. Results published to date imply that possible side effects of NVX-CoV2373 include tenderness and pain at the injection site, headaches, fatigue and muscle pain. But those same side effects occurred with complex tests from other coronavirus vaccine applicants. These side effects are also not unusual with vaccines approved for other viral infections.
NVX-CoV2373 is composed of what is called a “protein subunit” – a remote protein of the new coronavirus that causes COVID-19 – with an adjuvant to stimulate the receptor’s immune reaction to this protein. A similar technique has already been used with FDA-approved vaccines for other diseases. Two of Novavax’s rival complexes are a messenger RNA (mRNA) technique that has never been used before in an FDA-approved vaccine.
In an initial clinical study, the Novavax candidate induced neutralizing antibodies, the type that can prospectively protect against coronavirus infection, in one hundred percent of participants. The Matrix-M adjuvant used through Novavax also induced physically powerful T mobile responses, some signal of forward-looking efficiency. These effects led several analysts to explain their prospects that the Novavax coronavirus vaccine may simply be “the most productive of its kind. “
It remains to be noted whether NVX-CoV2373 will eventually be approved through regulators and will capture the highest percentage of place on the market among coronavirus vaccines However, there is a smart possibility that Novavax can beat its biggest rivals in terms of inventory market. He is already the biggest winner of the coronavirus vaccine race so far this front year and is not even a close competition.
All Novavax wants to do to keep winning is for NVX-CoV2373 to work well in complex tests. From what we’ve noticed so far, the chances of that diminishing deserve to be good. Historically, the maximum number of vaccines (nearly 3 out of four) successful in Phase 3 of clinical trials have been approved by the FDA.
The good luck of Novavax’s COVID-19 vaccine will almost lead to an increase in biotechnology actions. Since the company’s market capitalization is still well below that of its main competitors, Novavax’s percentage value is likely to increase particularly more than the percentages of other coronavirus vaccine leaders if their vaccines work well. The small extension of Novavax is not a disadvantage for investors; that’s an advantage.